Cytokinetics
CYTK
311 hedge funds and large institutions have $4.55B invested in Cytokinetics in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 143 increasing their positions, 104 reducing their positions, and 71 closing their positions.
371% more call options, than puts
Call options by funds: $216M | Put options by funds: $45.9M
38% more repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 104
0.19% more ownership
Funds ownership: 115.09% → 115.28% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
12% less funds holding
Funds holding: 355 → 311 (-44)
18% less capital invested
Capital invested by funds: $5.58B → $4.55B (-$1.03B)
61% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$266M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.1M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$32.6M |
| 4 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
+$32M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$69.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$59.9M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$52.7M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$50.5M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$35M |
CYTK Hedge Fund Activity: Q2 2025 in Review
311 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2025, worth a combined $4.55B — down 18% from $5.58B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of CYTK and 28 opened new positions — a net loss of 43 holders — while 104 trimmed existing stakes and 143 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $266M. The largest seller was Marshall Wace, cutting an estimated $69.8M.
- 311 institutional investors held Cytokinetics (CYTK) as of Q2 2025, down from 355 in Q1 2025.
- Funds reported $4.55B of Cytokinetics stock for Q2 2025, down 18% quarter-over-quarter.
- 28 funds opened new Cytokinetics positions in Q2 2025 and 71 closed out, a net change of -43 holders.
- The largest Cytokinetics buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $266M added.
- The largest Cytokinetics seller in Q2 2025 was Marshall Wace, an estimated $69.8M sold.
Based on aggregated 13F filings for Q2 2025.